Synthesis and characterization of physicochemical and immunological properties of recombinant NS3-G2 dendrimer conjugate

Javadi F¹, Rahimi P², Modaressi MH¹#, Shafiee Ardestani M¹, Bolhassani A², Aghasadeghi MR², Sadat SM²

¹Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
²Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
³Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT

Introduction: An effective vaccine against HCV infection is not available. The non-structural protein 3 (NS3) of the virus as an important immunogenic candidate has been utilized in various modules. Nanostructured polymers have been recently used for efficient vaccine and drug delivery. The aim of the current study was the synthesis of rNS3-G2 conjugate and preliminary evaluation of its immunogenicity. Methods: The dendrimer was synthesized and conjugated with purified recombinant NS3 (rNS3) protein. The physicochemical properties of the conjugate were evaluated by Zeta potential, FT-IR spectra and confirmed by atomic force microscopy (AFM). Immunogenicity of the conjugate was assessed in BALB/c mice. Results: Synthesis and conjugation of dendrimer G2 with the protein were confirmed and immunological assays showed that the conjugated form of the antigen induced higher titer of IgG compared to rNS3 antigen alone. Conclusion: The results showed that the antigenic structure of rNS3 was maintained when conjugated with the biodegradable and biocompatible G2 dendrimers and the immunogenic properties of the antigen were enhanced. Therefore the new formulation may have potential as a vaccine candidate.

KEYWORDS: Adjuvant, Dendrimer G2, rNS3, HCV, Conjugate.

INTRODUCTION

Hepatitis C virus (HCV) infection is a major public health concern with more than 170 million infected individuals worldwide of which approximately 70% remain infected for life [1]. Unfortunately, an effective vaccine against HCV is not available and although treatments with direct acting antivirals (DAAs) have shown a high rate of virological cure, the high costs and development of resistance make an effective therapeutic or prophylactic vaccine against the infection a necessity [2]. HCV is a positive-sense single strand RNA virus with approximately 9.6 kbp genome, encoding a poly protein of 3000 amino acids long. The encoded poly protein is cleaved by viral and host proteases [3, 4]. The non-structural protein 3 (NS3) is bi-functional containing serine protease and RNA helicase activity and is directly involved in the virus replication [5, 6]. The NS3 has been utilized as an important immune target in various vaccine and targeted antiviral therapy studies [7-11]. An effective vaccine for HCV infection should elicit strong cellular immune responses; however, subunit vaccines without a Th1-specific adjuvant formulation induce humoral responses, generally [12]. Several studies have shown that the use of particles in the nanoscale as carriers, in addition to stimulating humoral or cellular immunity, induces long-term immune responses [15-20]. Dendrimers are compact globular structures with advantageous properties including monodispersity, surface modification capabilities and the ability to control their sizes and molecular weights which make them ideal candidates to be used as carriers in the vaccine formulations [17, 21]. The aim of the current study was to synthesize rNS3-G2 conjugate and to evaluate its immunogenicity in BALB/c mice.

MATERIALS and METHODS

All the chemicals used were from Merck (Germany). The recombinant NS3 (rNS3) protein was prepared as previously described [22]. G2 dendrimer synthesis and conjugation with rNS3 protein

G2 dendrimer was synthesized as previously described [17]. Briefly, PEG600 was mixed with 3.72 mM Dicyclohexylcarbodiimide (DCC) dissolved in Dimethyl...
sulfoxide (DMSO). Citric acid (3.72 mM) was added to the mixture and the reaction was stopped by adding ddH2O. The solution was filtered through Watman filter paper (USA) and the filtrate was dialyzed for 16 h at room temperature against ddH2O. The dialyzed solution was freeze-dried and the G2 dendrimers (1 mM) were mixed with 5 mg/ml of purified rNS3 in an EDC mediated reaction for 24 h at 4°C. The conjugated NS3-G2 was purified by dialysis (Cutoff 10 kDa) and freeze-dried for further analysis.

Characterization of the physicochemical properties of conjugated rNS3-G2

FT-IR spectra were measured on a Bruker Model Tensor-27 spectrometer (Japan). To determine the size distribution and charge of the conjugated NS3, particle size and Zeta potential were measured using Malvern Nano-ZS (UK) at 24°C and water was used as a dispersant. Finally, AFM was used to study the structure and morphology of the conjugate.

Immunization Protocols

Pathogen-free, female BALB/c mice (weighting 18-20 g) were obtained from Pasteur Institute of Iran and handled according to the Pasteur Institute of Iran animal handling and care guidelines. Groups of seven mice were immunized subcutaneously (S.C.) in the tail base with 5 μg of rNS3 antigen (rNS3-Ag) or the conjugated form of the antigen suspended in 100 μl of PBS at weeks 0, 3 and 6. Mice blood samples were collected by retro-orbital bleeding two weeks post immunizations and the pooled sera were stored at −70°C till used.

Immunoassays by ELISA

The antibody responses of the immunized mice (total IgG and IgG isotypes) were analyzed by ELISA [23]. Briefly, ELISA plates (Nunc, Denmark) were coated with purified recombinant rNS3 (3μg/ml) and incubated overnight at 4°C. After three times washing and blocking steps with PBS-T buffer, an optimum dilution of the pooled sera (1:1000 dilution for total IgG and 1:2000 for isotypes), was added to each well and incubated for 1 h at 37°C, washed and further incubated with 1:10000 dilution of goat anti-mouse IgG-HRP conjugate (Sigma, USA) as secondary antibody. Finally, TMB (tetramethylbenzidine, Sigma, USA) was added and the absorbance was measured at 450 nm. Dilutions of 1:2000 of goat anti-mouse IgG1, IgG2a, IgG2b and IgG3 antibodies (Sigma, USA) and anti-goat IgG-HRP conjugate (1:10000) were used respectively as primary and secondary antibodies for the IgG isotypes.

Statistical analysis

All experiments were performed in triplicate and SPSS software (SPSS, ver. 23) was used for the statistical analyses. Values less than 0.05 (p<0.05) were considered significant.

RESULTS

Analysis of the rNS3-G2 conjugate

FT-IR spectra showed that 1726 cm⁻¹ peaks of carboxyl groups of citric acid in the dendrimer structure were suppressed to 1651 cm⁻¹ in rNS3-G2 conjugate which is an indicative of the amide bond formation between CO group of the citric acid and NH group of the surface amino acids in the conjugate (Fig.1A). Furthermore, AFM imaging confirmed the morphology and particle surface level differences between the G2 dendrimers and rNS3-G2 conjugate. A uniform and non-turbulent state in the form of nanoparticles was also observed which indicated a successful conjugation between the two entities (Fig.1B).

Fig.1. Physicochemical characterization of rNS3-G2 dendrimer conjugate. A) FT-IR spectra of G2 dendrimers in non-conjugated and conjugated forms with rNS3. B) AFM three-dimensional image of G2 dendrimers and rNS3-G2 conjugate.
Mean zeta potentials were obtained as -3.3 mV and 3.12 mV for G2 dendrimers and rNS3-G2, respectively. The size distributions were shown to be 90 nm and 215 nm for G2 dendrimers and rNS3-G2, respectively (Table 1).

**Table 1.** The charge and size distributions of the conjugated rNS3.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Size (nm)</th>
<th>Zeta Potential (mV)</th>
<th>PdI</th>
</tr>
</thead>
<tbody>
<tr>
<td>G2</td>
<td>90 ± 4.5</td>
<td>-3.3 ± 0.5</td>
<td>0.899</td>
</tr>
<tr>
<td>rNS3-G2</td>
<td>251.5 ± 12</td>
<td>3.12 ± 0.5</td>
<td>0.814</td>
</tr>
</tbody>
</table>

Furthermore, a statistically significant difference in total IgG response was observed in the group immunized with the conjugated protein compared to those that received rNS3 alone (Fig. 2A). The analysis of specific IgG isotypes indicated that IgG2a was the predominant subclass in the group immunized with rNS3-G2 (Fig. 2B).

**DISCUSSION**

Infection with HCV is a worldwide health concern and so far no promising vaccine against the infection is available [24]. Potent new direct acting antivirals (DAAs) have dramatically improved the success rates in disruption of the viral replication; however, high costs, side effects, and treatment failures still remain the main issues, underscoring the importance of developing therapeutic/prophylactic vaccines [25]. Several studies have shown that NS3 protein is a promising antigen for the purpose of anti-HCV vaccine development [26, 27]. However, subunit vaccines induce a lower immune response compared to whole cell vaccines, requiring improved vaccine carriers/adjuvants [28]. Dendrimer nanoparticles with a uniform small size (about 90 nm) and many functional groups on the surface have been proposed as suitable carriers/adjuvants for presentation of subunit antigens [28]. The adjuvant effect of nanoparticles may include prolonged presentation, enhanced antigen uptake and direct stimulation of the innate immune system [29].

In this study, the G2 dendrimer nanoparticles were used as carriers and adjuvants and the immunogenicity of the conjugated protein was assessed in BALB/c mice. The size and Zeta potential of the rNS3-G2 compared to G2 alone showed that the conjugation reaction between the two components has occurred (Table 1). Moreover, AFM results further confirmed the conjugation between G2 and rNS3 (Fig.1). A suitable adjuvant can induce innate immune response, as well as specific cellular or humoral immune responses when formulated with a common antigen [30]. Currently, the only approved adjuvant for use in humans is an aluminum compound (i.e. alum) which leads to poor immune responses, requires multiple boosters and produces mainly a Th2- immune response [31]. Therefore, finding new adjuvants for use in humans is necessary. Our immunoassay analyses indicated that specific-IgG titer in mice immunized with rNS3-G2 was significantly higher than rNS3 alone (p < 0.009). Our result also showed that rNS3-G2 induces a Th1/Th2 mixed immunity with a higher level of IgG2a subtype production. In conclusion, our preliminary data exhibited that a new conjugated form of rNS3 protein with dendrimer G2, generated by chemical reactions, was capable of inducing higher immune responses compared to the non-conjugated antigen.

**ACKNOWLEDGEMENT**

The study was supported by Hepatitis and AIDS Department of Pasteur Institute of Iran (Grant No: 832) and was part of a Ph.D. program. We thank Dr. Salimi and Dr. Ahangari Kohan for their advice. These data was partially presented in 9th national biotechnology congress of Islamic Republic of Iran, 22–23 May 2015 Tehran-Iran.

**CONFLICT OF INTEREST**

The authors declare that they have no conflict of interest.

**REFERENCES**

1. Larijani MS, Sadat SM, Nikbin M, Talebi SS, Javadi F, Mohajel N et al. Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP)...


